Published in J Pharm Policy Pract on October 26, 2016
Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess (2004) 29.45
Antimicrobial peptides of multicellular organisms. Nature (2002) 23.50
Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med (2013) 20.65
Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther (2007) 5.79
Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA (2012) 4.57
Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol (2013) 4.46
Monoclonal antibody successes in the clinic. Nat Biotechnol (2005) 4.43
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2008) 4.13
Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis (2011) 4.09
The biology and future prospects of antivirulence therapies. Nat Rev Microbiol (2008) 3.83
Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA (2014) 3.66
AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol (2009) 3.40
Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med (2012) 3.14
Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol (2006) 2.95
Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol (2012) 2.92
Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics (2010) 2.58
Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA (2015) 2.45
The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review. Crit Care Med (2009) 2.35
Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis (2008) 2.11
Antibacterial properties of nanoparticles. Trends Biotechnol (2012) 2.11
Arming the enemy: the evolution of resistance to self-proteins. Microbiology (2003) 1.95
Exploring the evidence base for national and regional policy interventions to combat resistance. Lancet (2015) 1.80
Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol (2000) 1.77
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med (2014) 1.76
Reducing infections through nanotechnology and nanoparticles. Int J Nanomedicine (2011) 1.72
Access to effective antimicrobials: a worldwide challenge. Lancet (2015) 1.64
Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol (2010) 1.62
Understanding the mechanisms and drivers of antimicrobial resistance. Lancet (2015) 1.52
Fecal microbiota transplantation--an old therapy comes of age. N Engl J Med (2013) 1.50
Point-of-care molecular diagnostic systems--past, present and future. Curr Opin Microbiol (2005) 1.43
Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis (2016) 1.37
Antibiotic-loaded biomaterials and the risks for the spread of antibiotic resistance following their prophylactic and therapeutic clinical use. Biomaterials (2010) 1.35
Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol (2008) 1.34
2012 and beyond: potential for the start of a second pre-antibiotic era? J Antimicrob Chemother (2012) 1.34
Clinical indications for probiotics: an overview. Clin Infect Dis (2008) 1.32
Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol (2010) 1.24
Phage therapy gets revitalized. Nature (2014) 1.24
Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis (2006) 1.22
Controlling the release of peptide antimicrobial agents from surfaces. Biomaterials (2009) 1.15
Backgrounds of antibiotic-loaded bone cement and prosthesis-related infection. Biomaterials (2004) 1.13
Regulatory oversight and safety of probiotic use. Emerg Infect Dis (2010) 1.13
Diagnostics as essential tools for containing antibacterial resistance. Drug Resist Updat (2011) 1.12
Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents (2010) 1.11
Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care (2008) 1.10
Finding alternatives to antibiotics. Ann N Y Acad Sci (2014) 1.09
Toxicology and clinical potential of nanoparticles. Nano Today (2011) 1.05
Fighting bacterial infections-future treatment options. Drug Resist Updat (2011) 1.05
International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet (2015) 1.05
Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005. J Antimicrob Chemother (2006) 1.04
Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries. Lancet (2015) 0.97
The factors affecting effectiveness of treatment in phages therapy. Front Microbiol (2014) 0.96
Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol (2008) 0.96
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2008) 0.95
Recent advances in materials for extended-release antibiotic delivery system. J Antibiot (Tokyo) (2011) 0.95
Silver nanoparticles as an alternative strategy against bacterial biofilms. Acta Biochim Pol (2013) 0.93
Virulence-targeted Antibacterials: Concept, Promise, and Susceptibility to Resistance Mechanisms. Chem Biol Drug Des (2015) 0.92
Antimicrobial peptides: promising alternatives to conventional antibiotics. J Mol Microbiol Biotechnol (2011) 0.91
Facilitators and barriers in pain management for trauma patients in the chain of emergency care. Injury (2011) 0.86
The evolution of the regulatory framework for antibacterial agents. Ann N Y Acad Sci (2014) 0.85
Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist (2014) 0.85
Mode of action of an antimicrobial biomaterial for use in hydrocephalus shunts. J Antimicrob Chemother (2004) 0.84
Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics (2014) 0.84
Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis (1996) 0.83
In vitro microbial inhibition and cellular response to novel biodegradable composite wound dressings with controlled release of antibiotics. Acta Biomater (2010) 0.83
New perspectives for a new century: implications of pathogen responses for the future of antimicrobial therapy. J Burn Care Res (2006) 0.80
Beyond Antibiotics: New Therapeutic Approaches for Bacterial Infections. Clin Infect Dis (2016) 0.80
Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. Curr Med Chem (2012) 0.78
Antibiotics: achieving the balance between access and excess. Lancet (2015) 0.76
Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance. Clin Infect Dis (2016) 0.76
Economic barriers to implementation of innovations in health care: is the long run-short run efficiency discrepancy a paradox? Health Policy (2008) 0.76
International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet (2015) 1.05
Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development. Infect Dis Rep (2017) 0.75
Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance. Clin Infect Dis (2017) 0.75